Superficial Parasternal Intercostal Plane Block With Ropivacaine Versus Placebo for Opioid Exposure After Cardiac Surgery (EPOCH CardioLink-10): A Multicentre, Double-Blind, Randomised Trial

In the EPOCH CardioLink-10 trial, 318 adults undergoing cardiac surgery via median sternotomy were included in a modified intention-to-treat analysis across four Canadian centers. Patients received bilateral superficial parasternal intercostal plane blocks with 0.2 percent ropivacaine or placebo via indwelling catheters for 48 hours. Ropivacaine reduced cumulative opioid use at 72 hours vs the placebo, with mean use of 122.8 vs 145.9 morphine milligram equivalents (MMEs) and a least-squares…